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The aim was to characterise RQ-00201894, a novel non-macrolide motilin agonist, using human re-
combinant receptors and then investigate its ability to facilitate cholinergic activity in human stomach. A
reporter gene assay assessed motilin receptor function. Selectivity of action was determined using a
panel of different receptors, ion channels, transporters and enzymes. Cholinergically-mediated muscle
contractions were evoked by electrical ﬁeld stimulation (EFS) of human gastric antrum. The results
showed that RQ-00201894, motilin and erythromycin acted as full motilin receptor agonists (EC50: 0.20,
0.11, 69 nM, respectively). In this function, RQ-00201894 had >90-fold selectivity of action over its ability
to activate the human ghrelin receptor (EC50 19 nM) and greater selectivity over all other receptors/
mechanisms tested. In human stomach RQ-00201894 0.1e30 mM concentration-dependently increased
EFS-evoked contractions (up to 1209%; pEC50 6.0). At 0.1e10 mM this activity was usually prolonged. At
higher concentrations (3e30 mM) RQ-00201894 also caused a short-lasting muscle contraction,
temporally disconnected from the increase in EFS-evoked contractions. RQ-00201894 10 mM did not
consistently affect submaximal contractions evoked by carbachol. In conclusion, RQ-00201894 potently
and selectively activates the motilin receptor and causes long-lasting facilitation of cholinergic activity in
human stomach, an activity thought to correlate with an ability to increase gastric emptying.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The gastrointestinal (GI) hormone motilin is released from the
upper gastrointestinal tract during hunger to evoke large,
migrating contractions of the stomach which represent phase III of
a pattern of GI movements during hunger, known as the migrating
motor complex (MMC) (1). Further, this release of motilin may
contribute to the mechanisms by which the sensation of hunger is
initiated (2). Interestingly, however, motilin receptor agonists are
also the target for developing new drugs which cause prolonged
stimulation of gastric emptying of meals. This follows the discovery,
in 1989, that the anti-biotic drug erythromycin is a non-selective.
rmacological Society.
. Production and hosting by Elsemotilin receptor agonist (3), followed by its subsequent ‘off label’
use as a gastric prokinetic agent (e.g. treating patients with gas-
troparesis, helping to control blood glucose levels in diabetic pa-
tients and increasing gastric emptying in patients receiving enteral
feeding or requiring clearance of gastric contents before endoscopy
or emergency surgery and its use in critically ill patients needing
rapid intubation) (1). In addition, azithromycin, another antibiotic
drug which activates the motilin receptor, is used to treat certain
patients with gastro-oesophageal reﬂux, where increasing gastric
emptying facilitates clearance of acid from the oesophagus (4).
Nevertheless, there is concern that antibiotic drugs should not be
used when there is no infection to treat, since this may contribute
to growing anti-bacterial drug resistance (5). Erythromycin and
azithromycin also have additional actions (e.g. inhibition of puri-
nergic P2X channels and cytochrome 3A4 by erythromycin, and in
rare cases, the potential for cardiac QT prolongation, arrhythmia
and sudden cardiac death by erythromycin and azithromycin) (1, 4,vier B.V. This is an open access article under the CC BY-NC-ND license (http://
J. Broad et al. / Journal of Pharmacological Sciences 130 (2016) 60e65 616, 7). Finally, the optimal doses required to treat patients with
gastroparesis are not rigorously established, with most in-
vestigators now using doses which are lower than those required to
treat infections, an approach which appears to retain gastric pro-
kinetic activity with minimal adverse events such as the induction
of nausea (1).
Progress in identifying a non-antibiotic drug which acts selec-
tively at the motilin receptor has been slow; as yet, no selective
motilin receptor agonist has entered clinical practice. In part, the
slow progress can be attributed to the complex macrolide struc-
tures of erythromycin, azithromycin and related molecules. This
complexity greatly impedes the ability to undertake the precise
structure-activity studies needed to optimise the selectivity of ac-
tion, efﬁcacy and duration of action of a motilin receptor agonist
suitable for clinical use, in addition to the pharmacokinetic char-
acteristics which enable such a molecule to become a successful
drug (8). Thus, the identiﬁcation of motilin receptor agonists with
simpler structures, including those derived from dihydro-
triazolopyridazine-1,3-dione-based amino acids (9) and more
recently, the low molecular weight receptor agonist, camicinal
(GSK962040 (10)) are now providing improved opportunities to
develop effective motilin receptor agonists and successful drugs.
RQ-00201894 is a new non-macrolide, small molecule motilin
receptor agonist (11). The pharmacology of RQ-00201894 is now
deﬁned in terms of its potency, efﬁcacy and selectivity at the human
motilin receptor. In addition, the ability of RQ-00201894 to facili-
tate gastric cholinergic motor transmission has been characterised
using human isolated stomach. This is an important assay not just
because it reﬂects the functions of the main excitatory motor
nerves within the stomach, but because it also identiﬁes motilin
receptor agonists which induce either a long-lasting facilitation of
cholinergic activity, more suitable for a gastric prokinetic drug or,
like motilin itself, induce a shorter-lasting facilitation consistent
with its role in mediating phase III MMC activity (12). Some of the
data have previously been presented as meeting abstracts (13, 14).
2. Materials and methods
2.1. Activity of RQ-00201894, motilin and erythromycin at the
human recombinant motilin receptor
CHO cells stably expressing both NFAT/b-lactamase reporter
gene and humanmotilin receptor were seeded into 384-well black/
clear-bottom plates. After overnight incubation, the culture me-
dium was replaced by serum free medium at 37 C for 1.5 h. The
cells were then treated with the motilin receptor agonists at 37 C
for 4.5 h. Afterwards, CCF4/AM, a ﬂuorogenic substrate (Invitrogen)
was added and the cells incubated for 2 h. The ﬂuorescence in-
tensities were measured (Functional Drug Screening System;
Hamamatsu Photonics) with excitation at 405 nm and emission at
465 and 540 nm. The concentration-response curves for RQ-
00201894, motilin, and erythromycin were expressed as a per-
centage of the maximal control activity (50 mM erythromycin), and
analyzed using GraphPad Prism (GraphPad Software) to obtain EC50
values. Data represent mean ± S.E.M. of three independent exper-
iments performed in duplicate.
2.2. Evaluation of selectivity of action
The activity of a single concentration of RQ-00201894 (10 mM)
was examined using a range of 64 different GPCRs, transporters,
enzymes and ion channels expressed in native tissues and cell lines
expressing human or rat recombinant proteins, provided by Cerep
(Cerep, Paris, France), using standard radioligand binding, func-
tional and enzyme assays. Speciﬁcally for the human ghrelinreceptor, at which the effects of a range of concentrations of RQ-
00201894 were studied, the receptors were transiently expressed
in HEK293 cells and after seeding into 96 well plates (20,000 cells/
100 ml/well) their function assessed using a Ca2þ inﬂux assay with
ﬂuorescence intensity measured as above, as a ratio of emission
intensities (510 nm from 340 nm excitation/510 from 380 nm). The
concentration-response curves of RQ-00201894 and human ghrelin
were expressed as percentage in proportion with maximal control
activity (1 mM human ghrelin).2.3. Human stomach
The method followed that which we have previously described
(12). In brief, segments of stomach were obtained from patients
undergoing surgery for obesity. The studywas approved by the East
London Research Ethics Committee 1, (REC reference number 10/
H0703/71, SSA reference number 10/H0703/76), and written
informed consent was obtained from all patients Tissues were
transferred to the laboratory within 2 h after resection in Krebs'
solution (mM: NaCl 121.5, CaCl2 2.5, KH2PO4 1.2, KCl 4.7, MgSO4 1.2,
NaHCO3 25, glucose 5.6) equilibrated with 5% CO2 and 95% O2 and
were used immediately or after overnight storage at 4 C in fresh,
oxygenated Krebs' solution.
The mucosa, muscularis mucosa and submucosal plexus were
removed by blunt dissection. Strips of gastric antrum
(3e5  15 mm) were cut approximately parallel to the circular
muscle ﬁbres and mounted in tissue baths (containing Krebs so-
lution at 35 C, gassed with 5% CO2 in O2) for measurement of
changes in muscle tension using pre-calibrated isometric force
transducers (AD Instruments, Chalgrove, UK) linked to a data
acquisition system (Biopac Inc., CA, USA). After an initial application
of 2 g tension the strips were allowed to recover for 60 min, during
which the bath solutions were changed every 15 min. The strips
were then stimulated via two parallel platinum ring electrodes
connected to a stimulator (STG2008, Scientiﬁca, Uckﬁeld, UK).
Electrical ﬁeld stimulation (EFS) was applied at 5 Hz for 10 s using
50 V (c.200 mA) and 0.5 m bipolar pulse duration, repeated every
1 min. These parameters evoked monophasic, cholinergically-
mediated contractions, attenuated by simultaneous activation of
nitrergic inhibitory neurons (12), and were applied continuously
until consistent responses were obtained (bath solution changed
every 15 min).
In the experiments to examine the effects of RQ-00201894 on
EFS-evoked contractions, each strip of stomach muscle was
exposed to only a single concentration of RQ-00201894, which was
then left in contact with the tissue for at least 60min. The following
measurements were taken:
1 Change in baseline muscle tension (expressed as a % of at least
three pre-treatment EFS-induced contractions) and duration of
any change,
2 Maximum change in EFS-evoked contractions (determined by
measuring at least three EFS-induced responses at a given time-
point, expressed as a percentage of the mean of at least three
pre-treatment EFS-induced responses (100%)) and the time
taken to achieve maximum response,
3 The length of time over which the maximum increase in EFS-
evoked contraction was maintained during the continuous
presence of the compound, measuring the time of fade of
response if appropriate,
4 The occurrence of irregular contractions in response to EFS after
application of RQ-00201894, recorded as a simple presence or
absence.
Fig. 1. Concentration-response curves of RQ-00201894, human motilin, and
erythromycin at human motilin receptors expressed in CHO cells, obtained using a
b-lactamase reporter gene assay. Data represent percentage relative to the maximal
control activity at 50 mM erythromycin and show arithmetic mean ± SEM of three
independent variables.
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00201894 on contractions evoked by carbachol, a concentration
of 1 mM carbachol was used (representing the concentration
causing ~50% of maximum contraction; data not shown) and
consistent responses were obtained (5 min contact, repeated at
15 min intervals) before RQ-00201894 was added.Fig. 2. Representative experimental records showing the responses of circular muscle s
contractions are shown in response to EFS (50 V, 0.5 m bipolar pulse duration, 5 Hz) give
00201894.2.4. Statistical analysis
Data obtained from experiments using the recombinant re-
ceptors are expressed as geometric means with 95% conﬁdence
ranges. Curves were ﬁtted using a 4 parameter (log) agonist
response curve. Data obtained from the human stomach experi-
ments are expressed as medians and ranges or as the
mean ± standard error of the mean; n values are the numbers of
patients. Curves were ﬁtted using a 3 parameter (log) agonist
response curve. Changes of baseline tension, EFS magnitude and
responses to carbachol were compared usingWilcoxon signed rank
tests. P < 0.05 is considered as statistically signiﬁcant. All data were
analysed using GraphPad Prism 5.
2.5. Drugs
In the experiments using the recombinant motilin and ghrelin
receptors, RQ-00201894 and erythromycin were dissolved and
diluted with 100% DMSO before ﬁnal addition to the appropriate
assay buffer Motilin receptor assay: 100 ml of HBSS (1000 mlþ 1 M
HEPES 20 ml), 5 ml BSA (20 mg/ml) and 1 ml DMSO; Ghrelin re-
ceptor assay: 100 ml of HBSS (1000 ml þ 1 M HEPES 20 ml) and
adding to the cells. Human motilin was dissolved with distilled
water before serial dilution using 100% DMSO and assay buffer, as
above. Human ghrelin was dissolved with distilled water. For all
other experiments with recombinant receptors, RQ-00201894 wastrips of human antrum to the continuous presence of 1e30 mM RQ-00201894. The
n for 10 s, every 1 min. Note the different response kinetics after application of RQ-
Fig. 3. Effects of RQ-00201894 on contractions to EFS in circular muscle strips from
human gastric antrum. Panel A displays the concentration relationship of the facili-
tation of EFS by RQ-00201894 0.001e30 mM. Panel B displays the concentration rela-
tionship of the increase in baseline muscle tension induced by RQ-00201894. EFS
(50 V, 0.5 m bipolar pulse duration, 5 Hz) was given for 10 s, every 1 min. n ¼ 4e6
patients for each concentration; drugs were applied non-cumulatively.
J. Broad et al. / Journal of Pharmacological Sciences 130 (2016) 60e65 63dissolved in 100% DMSO at 10 mM. In the experiments using hu-
man stomach, all drugs were freshly prepared prior to use. Carba-
chol and RQ-00201894 were dissolved in dH2O.
3. Results
3.1. Activity of RQ-00201894 at the recombinant human motilin
receptor
RQ-00201894, motilin and erythromycin were equi-effective as
motilin receptor agonists, the Emax values for RQ-00201894 and
motilin being similar to the activity evoked by the maximum
concentration of erythromycin (50 mM) (Fig. 1). In this assay, the
EC50 values for RQ-00201894, motilin and erythromycin were,
respectively, 0.20 (geometric mean with 95% conﬁdence limits:
0.19e0.22), 0.11 (0.07e0.19) and 69 (51e94) nM; the Emax values
were 101 (99e103), 97 (95e100)% and 98 (95e101)%; and the Hill
slopes were 1.5 (1.3e1.7); 1.9 (1.5e2.3) and 1.9 (1.6e2.3) all from 3
independent experiments performed in triplicate.
3.2. Selectivity data
RQ-0020189410 mMhad little or no activity when tested against
a Cerep panel of 64 receptors, ion channels and enzymes. In the
binding studies the exception was the Naþ channel (IC50 1.5 mM). In
the functional assays the exception was the 5-HT1B receptor (EC50
8.6 mM). Further, RQ-00201894 acted as an agonist at the human
ghrelin receptor but at concentrations approximately 95 times
higher than those required to activate the motilin receptor (EC50 19
(geometric mean with 95% conﬁdence limits: 11e34) nM at the
ghrelin receptor, compared with 4.9 (2.0e12) nM for ghrelin itself;
n ¼ 3 independent experiments).
3.3. Effect in human stomach
52 strips of human isolated antrum muscle were obtained from
8 patients undergoing sleeve gastrectomies for obesity. The male to
female ratio was 1:1; median age (range) ¼ 51 (25e60). 3 tissues
were used on the same day as the operation, and 5 were used
following overnight storage in fresh oxygenated Krebs solution at
4 C, following removal of the mucosa.
After achieving consistent responses to EFS (obtained after 208
(189e256) minutes), the application of RQ-00201894 0.1e30 mM
concentration-dependently increased the amplitude of the EFS-
evoked contractions (Figs. 2 and 3; Table 1), with an Emax of
1209 ± 183% and a pEC50 ¼ 6.0 ± 0.4, n ¼ 4e6 patients for each
concentration; P ¼ 0.03 at 10 mM; lower concentrations (0.001,
0.01 mM) had no consistent activity. At low concentrations
(0.1e10 mM) this excitatory action of RQ-00201894 was slow in
onset and after reaching maximum, was usually maintained for the
remainder of the experiment; at the highest concentration (30 mM)
the response faded during the continued presence of the com-
pound (Figs. 2 and 4; Table 1). Notably, the facilitation of the EFS-
evoked responses did not always occur in a regular manner, with
large and small EFS-evoked contractions appearing at irregular
intervals especially at the higher concentrations (Figs. 2 and 4).
Relatively higher concentrations of RQ-00201894 (3e30 mM)
also consistently evoked a short-lasting muscle contraction (an
Emax of 292 ± 76% and a pEC50¼ 5.9 ± 0.6, n¼ 4e6 patients for each
concentration; P ¼ 0.03 at 10 mM; n ¼ 6) which appeared tempo-
rally disconnected from the increase in EFS-evoked contractions,
reaching maximum more quickly and usually fading completely
before the increase in EFS-evoked contraction had reached
maximum (Figs. 2 and 3; Table 1); the lower concentrations of RQ-00201894 contracted the muscle in 2 of 5 tissues at 1 mM, in 3 of 5
tissues at 0.3 mM and in 2 of 6 tissues at 0.1 mM.
In separate experiments, RQ-00201894 10 mM had no consistent
ability to affect the magnitude of contractions evoked by a
submaximally-effective concentration of carbachol (1 mM; con-
tractions were 83 ± 13% of the responses before RQ-00201894
addition; n ¼ 4, P > 0.05).4. Discussion
RQ-00201894 demonstrated good potency as an agonist at the
human recombinant motilin receptor expressed in CHO cells, as
well as selectivity of action when compared with the higher con-
centrations needed to activate the ghrelin receptor and more
especially, interact with a range of other GPCRs, transporters, ion
channels and enzymes. This selectivity of action as a motilin re-
ceptor agonist contrasts with the non-selective activity for eryth-
romycin, azithromycin and other macrolide structures with
antibiotic and motilin receptor agonist activity (1, 4, 6, 7; see
Introduction for details). The potency of RQ-00201894 as a motilin
receptor agonist in this assaywas similar to that ofmotilin itself and
>300 times greater than the potency demonstrated by erythro-
mycin. It is likely that RQ-00201894 binds to the orthosteric bind-
ing site of the motilin receptor, as increasing concentrations of GM-
109 (15) have been previously demonstrated to cause surmount-
able rightward shifts in the concentration-response curves to RQ-
00201894 in the NFAT/b-lactamase assay (13).
In human isolated gastric antrum, RQ-00201894 0.1e30 mM
concentration-dependently facilitated cholinergically-mediated
contractions. This activity was slow to reach maximum and once
achieved, was usually prolonged (with the exception of 30 mM, the
highest concentration tested, where fade was clearly observed
during the experiments). Notably, the potency of RQ-00201894 in
Table 1
Summary of effects of RQ-00201894 on baseline muscle tension and on neuronally-
mediated contractions during electrical ﬁeld stimulation in human isolated colon.
Muscle [n] Nerve [n]
Effective concentrations 0.3e30 mM [5e6] 0.1e30 mM [5e6]
pEC50
(mean ± standard error)
5.9 ± 0.5 [4e6] 6.0 ± 0.4 [4e6]
Emax (%)
(mean ± standard error)
292 ± 76* [4e6] 1209 ± 183 [4e6]
Tmax at 10 mM (min)
(median, with range)
10 (5e16) [6] 44 (10e51) [6]
Tfade at 10 mM (min)**
(median, with range)
29 (12e51) [6] not observed [5] except
in one tissue where the
Tmax was short (10 min)
and fade occurred
within 17 min
The values shown are determined from a concentration-response curve for RQ-
00201894 (0.001e30 mM) constructed by adding single concentrations of the
compound to separate tissues; n ¼ 4e6 patients for each concentration. * % of
contraction amplitude evoked by EFS prior to addition of RQ-00201894. ** the time
at which the response faded is recorded as the point at which the increase in muscle
tension had completely returned to baseline, or for EFS as the point at which the
facilitation had declined by 50%.
J. Broad et al. / Journal of Pharmacological Sciences 130 (2016) 60e6564the human gastric antrum was lower than that when tested at the
human recombinant receptor (respectively, pEC50 values of 6.0 and
9.5). Similar differences in potencies have previously been reported
for motilin, erythromycin, azithromycin and camicinal when
comparing data obtained using recombinant receptors and human
isolated stomach (4, 12), perhaps reﬂecting the additional need for
these compounds to penetrate into the muscle and reach the
motilin receptors on the cholinergic nerves. RQ-00201894 also
evoked small increases in muscle tension. These contractions
occurred consistently at concentrations (3e30 mM) which wereFig. 4. Duration of facilitation by RQ-00201894 of EFS-evoked contractions in circular m
consecutive contractions were calculated consecutively throughout the experiment. Pane
00201894 1e30 mM respectively. Note the different response kinetics and the irregularity
occurred in-between larger contractions), particularly at the higher concentrations. EFS (50
for each concentration as displayed on panels.higher than the threshold concentrations which increased EFS-
evoked contractions, although at lower concentrations somedbut
not alldtissues contracted in response to RQ-00201894. Notably,
the contractions were relatively rapid in onset and usually faded
completely before RQ-00201894 had maximally increased EFS-
evoked contractions. Such activity is consistent with the actions
of other motilin receptor agonists in human stomach (4, 12). The
different neuronal and muscle responses are thought to represent
the main motor pathways by which low doses of motilin receptor
agonists increase gastric emptying (by facilitation of cholinergic
activity) or when given at higher doses, directly contract the
stomach muscle to induce early satiety and nausea (exempliﬁed by
the use of erythromycin at the relatively high doses required for
antibiotic treatment) (1).
In human stomach, RQ-00201894 is likely to increase cholin-
ergic activity by facilitating the release of acetylcholine from the
intrinsic cholinergic neurons of the stomach. Thus, in commonwith
other motilin receptor agonists (4, 12) a high concentration of RQ-
00201894 had no consistent ability to modulate the contractions
evoked by a submaximally-effective concentration of carbachol.
Notably, the increase in cholinergic activity by RQ-00201894 can
occur in a prolonged manner. A broadly-similar long-lasting ac-
tivity has previously been reported for erythromycin and azi-
thromycin, drugs used to treat gastroparesis or increase gastric
emptying, and also camicinal, under development for treatment of
these disorders (4,12; see Introduction formore detail). By contrast,
a relatively short-lasting activity of motilin is consistent with its
physiological role in inducing the migrating phase III contractions
of the MMC (1, 4, 12, 16, 17). The explanation for these different
proﬁles of activity for motilin and the synthetic motilin receptor
agonists is unclear but ‘functional’ or ‘biased’ agonism has been
hypothesised, with the molecules acting at one or more bindinguscle strips from human gastric antrum. For each tissue studied, the mean of three
ls AeD shows the time course of the mean ± S.E.M. response to application of RQ-
of contractions during fade of response to RQ-00201894 (in which small contractions
V, 0.5 m bipolar pulse duration, 5 Hz) was given for 10 s, every 1 min. n ¼ 5e6 patients
J. Broad et al. / Journal of Pharmacological Sciences 130 (2016) 60e65 65sites on the motilin receptor to differentially inﬂuence different
intracellular signalling pathways (18). Interestingly, the increase in
EFS-evoked contractions caused by RQ-00201894 was not always
consistent, especially at the higher concentrations tested, and the
contraction amplitudes became irregular. The reason why irregular
contractions should occur during EFS is unknown. One possibility,
discussed by Broad et al (12), is that the activities of different groups
of interstitial cells of Cajal (ICCs) within the intestinal wall become
uncoordinated so that overall, the baseline muscle electrical ac-
tivity rises and falls at a frequency which is markedly slower than
the frequency of EFS, inﬂuencing the amplitudes of the contractions
evoked by EFS. An ability of different groups of ICCs to move out of
synchrony with each other has previously been observed in human
isolated jejunum, a phenomenon linked to disordered GI move-
ments (19).
In other studies with RQ-00201894 in conscious fasted dogs, the
compound has been shown to induce high-amplitude contractions
of gastric antrum and duodenum (similar to the phase III-like ac-
tivity of the migrating motor complex (MMC) during hunger,
mediated by endogenous motilin) without causing vomiting and
even after suppression of spontaneous contractility by clonidine.
Further, RQ-00201894 increased gastric emptying of meals con-
taining acetaminophen in conscious dogs and cynomolgus mon-
keys (13, 20). Notably, the dog and human motilin receptors are
phylogenetically distinct (21) with only 71% protein sequence
identity between the two receptors and up to 2 log lower potencies
for different motilin receptor agonists at the dog receptor (22, 23).
Further, motilin receptor immunoreactivity has been detected
within the enteric nervous system (ENS) but not in the muscle of
dog stomach (21) whereas in humans motilin receptor immuno-
reactivity has been detected in both, with low concentrations of
motilin facilitating cholinergic activity and higher concentrations
directly contracting the muscle (12); these differences suggest
signiﬁcantly different dynamics of the response to motilin between
the two species.
In summary, RQ-00201894 demonstrates good agonist potency
and selectivity at the human motilin receptor and in human
stomach, facilitates cholinergic activity in a manner that is broadly
consistent with other non-peptide motilin receptor agonists. These
data suggest that RQ-00201894 will promote human gastric
emptying and should be evaluated as a potential new drug for
treatment of disorders such as gastroparesis and in other groups of
patients where there is a need to increase gastric emptying.
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